GlassScriptPhysician profile
Edward W Baumgartner
NPI 1548402407
$20,162.80
in general payments reported to CMS, 2019-2025
40 companies · $4,986 in 2025
The $4,986 reported for 2025 was more than what 91% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $414 · 2021: $1,031 · 2022: $3,285 · 2023: $3,765 · 2024: $3,686 · 2025: $4,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,717 · Travel and Lodging: $2,705 · Gift: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,717.39 |
| Travel and Lodging | $2,704.95 |
| Gift | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $11,626.00 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Spinal Simplicity, LLC | $1,512.97 | 2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $1,504.44 | 2019-2020 | |
| Boston Scientific Corporation | $983.31 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $785.71 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Nevro Corp. | $574.38 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $545.16 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Stryker Corporation | $336.10 | 2025 | Mild Device Kit |
| Abbvie INC. | $277.67 | 2023-2025 | Qulipta, Ubrelvy |
| Genesys Orthopedics Systems, L.L.C. | $215.11 | 2025 | Sacroiliac Joint Fusion System |
| Si-Bone, INC. | $207.93 | 2019-2022 | |
| Biotronik Nro, INC. | $206.85 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.47 | 2022-2024 | Relistor |
| Biodelivery Sciences International, INC. | $141.49 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $118.40 | 2019-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $117.41 | 2021-2024 | Tirosint, Licart, Licart |
| Arbor Pharmaceuticals, INC. | $84.23 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $80.29 | 2023-2024 | Horizant, Horizant |
| Convatec INC. | $77.58 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $62.48 | 2019 | |
| Amgen INC. | $62.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $46.70 | 2020-2021 | |
| Assertio Therapeutics, INC. | $40.90 | 2019 | |
| Painteq LLC | $40.77 | 2021-2023 | Painteq |
| Astrazeneca Pharmaceuticals LP | $40.16 | 2019 | |
| Spr Therapeutics, INC | $36.69 | 2025 | Sprint Pns System |
| Shionogi INC | $32.70 | 2019 | |
| Pfizer INC. | $30.20 | 2024 | |
| Merz North America, INC. | $24.39 | 2019 | |
| Zyla Life Sciences, INC. | $22.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.39 | 2019 | |
| Redhill Biopharma INC. | $20.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.34 | 2022 | |
| Protega Pharmaceutials INC | $16.75 | 2023 | Roxybond |
| Nalu Medical, INC. | $16.71 | 2023 | Nalu Neurostimulation System |
| Pernix Therapeutics Holdings, INC. | $16.45 | 2019 | |
| Curonix LLC | $16.33 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Allergan, INC. | $15.07 | 2020 | |
| Fidia Pharma USA INC. | $14.76 | 2025 | Hyalgan |
| Bioventus LLC | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Baumgartner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.